Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Reduced Function and Diversity of T Cell Repertoire and Distinct Clinical Course in Patients With IL7RA Mutation.

Lev A, Simon AJ, Barel O, Eyal E, Glick-Saar E, Nayshool O, Birk O, Stauber T, Hochberg A, Broides A, Almashanu S, Hendel A, Lee YN, Somech R.

Front Immunol. 2019 Jul 17;10:1672. doi: 10.3389/fimmu.2019.01672. eCollection 2019.

2.

c.259A>C in the fibrinogen gene of alpha chain (FGA) is a fibrinogen with thrombotic phenotype.

Salomon O, Barel O, Eyal E, Ganor RS, Kleinbaum Y, Shohat M.

Appl Clin Genet. 2019 Feb 28;12:27-33. doi: 10.2147/TACG.S190599. eCollection 2019.

3.

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.

Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington's Disease Network; Huntington Study Group investigators.

Lancet Neurol. 2019 Feb;18(2):165-176. doi: 10.1016/S1474-4422(18)30391-0. Epub 2018 Dec 15.

PMID:
30563778
4.

Immunomodulatory placental-expanded, mesenchymal stromal cells improve muscle function following hip arthroplasty.

Winkler T, Perka C, von Roth P, Agres AN, Plage H, Preininger B, Pumberger M, Geissler S, Hagai EL, Ofir R, Pinzur L, Eyal E, Stoltenburg-Didinger G, Meisel C, Consentius C, Streitz M, Reinke P, Duda GN, Volk HD.

J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):880-897. doi: 10.1002/jcsm.12316. Epub 2018 Sep 19.

5.

Pharmacokinetics and safety of single and multiple doses of rasagiline in healthy Japanese and caucasian subjects.

Elgart A, Rabinovich-Guilatt L, Eyal E, Gross A, Spiegelstein O.

Basic Clin Pharmacol Toxicol. 2019 Mar;124(3):273-284. doi: 10.1111/bcpt.13131. Epub 2018 Oct 21.

PMID:
30218626
6.

A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.

Spiegelstein O, Mimrod D, Rabinovich L, Eyal E, Sprenger C, Elgart A, Samara E, Morganroth J.

Clin Pharmacol Drug Dev. 2019 Jan;8(1):49-59. doi: 10.1002/cpdd.442. Epub 2018 May 22.

PMID:
29786964
7.

Mutations in PPCS, Encoding Phosphopantothenoylcysteine Synthetase, Cause Autosomal-Recessive Dilated Cardiomyopathy.

Iuso A, Wiersma M, Schüller HJ, Pode-Shakked B, Marek-Yagel D, Grigat M, Schwarzmayr T, Berutti R, Alhaddad B, Kanon B, Grzeschik NA, Okun JG, Perles Z, Salem Y, Barel O, Vardi A, Rubinshtein M, Tirosh T, Dubnov-Raz G, Messias AC, Terrile C, Barshack I, Volkov A, Avivi C, Eyal E, Mastantuono E, Kumbar M, Abudi S, Braunisch M, Strom TM, Meitinger T, Hoffmann GF, Prokisch H, Haack TB, Brundel BJJM, Haas D, Sibon OCM, Anikster Y.

Am J Hum Genet. 2018 Jun 7;102(6):1018-1030. doi: 10.1016/j.ajhg.2018.03.022. Epub 2018 May 10.

8.

Somatic NRAS mutation in patient with generalized lymphatic anomaly.

Manevitz-Mendelson E, Leichner GS, Barel O, Davidi-Avrahami I, Ziv-Strasser L, Eyal E, Pessach I, Rimon U, Barzilai A, Hirshberg A, Chechekes K, Amariglio N, Rechavi G, Yaniv K, Greenberger S.

Angiogenesis. 2018 May;21(2):287-298. doi: 10.1007/s10456-018-9595-8. Epub 2018 Feb 3.

PMID:
29397482
9.

Whole-genome sequencing reveals principles of brain retrotransposition in neurodevelopmental disorders.

Jacob-Hirsch J, Eyal E, Knisbacher BA, Roth J, Cesarkas K, Dor C, Farage-Barhom S, Kunik V, Simon AJ, Gal M, Yalon M, Moshitch-Moshkovitz S, Tearle R, Constantini S, Levanon EY, Amariglio N, Rechavi G.

Cell Res. 2018 Feb;28(2):187-203. doi: 10.1038/cr.2018.8. Epub 2018 Jan 12.

10.

RNA editing by ADAR1 leads to context-dependent transcriptome-wide changes in RNA secondary structure.

Solomon O, Di Segni A, Cesarkas K, Porath HT, Marcu-Malina V, Mizrahi O, Stern-Ginossar N, Kol N, Farage-Barhom S, Glick-Saar E, Lerenthal Y, Levanon EY, Amariglio N, Unger R, Goldstein I, Eyal E, Rechavi G.

Nat Commun. 2017 Nov 13;8(1):1440. doi: 10.1038/s41467-017-01458-8.

11.

Mutations in AIFM1 cause an X-linked childhood cerebellar ataxia partially responsive to riboflavin.

Heimer G, Eyal E, Zhu X, Ruzzo EK, Marek-Yagel D, Sagiv D, Anikster Y, Reznik-Wolf H, Pras E, Oz Levi D, Lancet D, Ben-Zeev B, Nissenkorn A.

Eur J Paediatr Neurol. 2018 Jan;22(1):93-101. doi: 10.1016/j.ejpn.2017.09.004. Epub 2017 Sep 15.

PMID:
28967629
12.

Deleterious variants in TRAK1 disrupt mitochondrial movement and cause fatal encephalopathy.

Barel O, Malicdan MCV, Ben-Zeev B, Kandel J, Pri-Chen H, Stephen J, Castro IG, Metz J, Atawa O, Moshkovitz S, Ganelin E, Barshack I, Polak-Charcon S, Nass D, Marek-Yagel D, Amariglio N, Shalva N, Vilboux T, Ferreira C, Pode-Shakked B, Heimer G, Hoffmann C, Yardeni T, Nissenkorn A, Avivi C, Eyal E, Kol N, Glick Saar E, Wallace DC, Gahl WA, Rechavi G, Schrader M, Eckmann DM, Anikster Y.

Brain. 2017 Mar 1;140(3):568-581. doi: 10.1093/brain/awx002. Erratum in: Brain. 2018 Apr 1;141(4):e34.

13.

Mutations in ERGIC1 cause Arthrogryposis multiplex congenita, neuropathic type.

Reinstein E, Drasinover V, Lotan R, Gal-Tanamy M, Bolocan Nachman I, Eyal E, Jaber L, Magal N, Shohat M.

Clin Genet. 2018 Jan;93(1):160-163. doi: 10.1111/cge.13018. Epub 2017 Jul 26.

PMID:
28317099
14.

MECR Mutations Cause Childhood-Onset Dystonia and Optic Atrophy, a Mitochondrial Fatty Acid Synthesis Disorder.

Heimer G, Kerätär JM, Riley LG, Balasubramaniam S, Eyal E, Pietikäinen LP, Hiltunen JK, Marek-Yagel D, Hamada J, Gregory A, Rogers C, Hogarth P, Nance MA, Shalva N, Veber A, Tzadok M, Nissenkorn A, Tonduti D, Renaldo F; University of Washington Center for Mendelian Genomics, Kraoua I, Panteghini C, Valletta L, Garavaglia B, Cowley MJ, Gayevskiy V, Roscioli T, Silberstein JM, Hoffmann C, Raas-Rothschild A, Tiranti V, Anikster Y, Christodoulou J, Kastaniotis AJ, Ben-Zeev B, Hayflick SJ.

Am J Hum Genet. 2016 Dec 1;99(6):1229-1244. doi: 10.1016/j.ajhg.2016.09.021. Epub 2016 Nov 3.

15.

Microcephaly, intractable seizures and developmental delay caused by biallelic variants in TBCD: further delineation of a new chaperone-mediated tubulinopathy.

Pode-Shakked B, Barash H, Ziv L, Gripp KW, Flex E, Barel O, Carvalho KS, Scavina M, Chillemi G, Niceta M, Eyal E, Kol N, Ben-Zeev B, Bar-Yosef O, Marek-Yagel D, Bertini E, Duker AL, Anikster Y, Tartaglia M, Raas-Rothschild A.

Clin Genet. 2017 May;91(5):725-738. doi: 10.1111/cge.12914. Epub 2016 Dec 16.

PMID:
27807845
16.

Congenital Sucrase-isomaltase Deficiency: A Novel Compound Heterozygous Mutation Causing Aberrant Protein Localization.

Haberman Y, Di Segni A, Loberman-Nachum N, Barel O, Kunik V, Eyal E, Kol N, Hout-Siloni G, Kochavi B, Avivi C, Schvimer M, Rechavi G, Anikster Y, Barshack I, Weiss B.

J Pediatr Gastroenterol Nutr. 2017 May;64(5):770-776. doi: 10.1097/MPG.0000000000001424.

PMID:
27749612
17.

A Novel Mutation in a Critical Region for the Methyl Donor Binding in DNMT3B Causes Immunodeficiency, Centromeric Instability, and Facial Anomalies Syndrome (ICF).

Rechavi E, Lev A, Eyal E, Barel O, Kol N, Barhom SF, Pode-Shakked B, Anikster Y, Somech R, Simon AJ.

J Clin Immunol. 2016 Nov;36(8):801-809. Epub 2016 Oct 12.

PMID:
27734333
18.

G23D: Online tool for mapping and visualization of genomic variants on 3D protein structures.

Solomon O, Kunik V, Simon A, Kol N, Barel O, Lev A, Amariglio N, Somech R, Rechavi G, Eyal E.

BMC Genomics. 2016 Aug 26;17:681. doi: 10.1186/s12864-016-3028-0.

19.

Mutations in STN1 cause Coats plus syndrome and are associated with genomic and telomere defects.

Simon AJ, Lev A, Zhang Y, Weiss B, Rylova A, Eyal E, Kol N, Barel O, Cesarkas K, Soudack M, Greenberg-Kushnir N, Rhodes M, Wiest DL, Schiby G, Barshack I, Katz S, Pras E, Poran H, Reznik-Wolf H, Ribakovsky E, Simon C, Hazou W, Sidi Y, Lahad A, Katzir H, Sagie S, Aqeilan HA, Glousker G, Amariglio N, Tzfati Y, Selig S, Rechavi G, Somech R.

J Exp Med. 2016 Jul 25;213(8):1429-40. doi: 10.1084/jem.20151618. Epub 2016 Jul 18.

20.

Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence.

Gilgun-Sherki Y, Eliaz RE, McCann DJ, Loupe PS, Eyal E, Blatt K, Cohen-Barak O, Hallak H, Chiang N, Gyaw S.

Drug Alcohol Depend. 2016 Sep 1;166:13-20. doi: 10.1016/j.drugalcdep.2016.05.019. Epub 2016 May 28.

21.

Loss of function of NaPiIIa causes nephrocalcinosis and possibly kidney insufficiency.

Dinour D, Davidovits M, Ganon L, Ruminska J, Forster IC, Hernando N, Eyal E, Holtzman EJ, Wagner CA.

Pediatr Nephrol. 2016 Dec;31(12):2289-2297. Epub 2016 Jul 4.

22.

Expanding the molecular diversity and phenotypic spectrum of glycerol 3-phosphate dehydrogenase 1 deficiency.

Dionisi-Vici C, Shteyer E, Niceta M, Rizzo C, Pode-Shakked B, Chillemi G, Bruselles A, Semeraro M, Barel O, Eyal E, Kol N, Haberman Y, Lahad A, Diomedi-Camassei F, Marek-Yagel D, Rechavi G, Tartaglia M, Anikster Y.

J Inherit Metab Dis. 2016 Sep;39(5):689-695. doi: 10.1007/s10545-016-9956-7. Epub 2016 Jul 1.

PMID:
27368975
23.

Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.

Masellis M, Collinson S, Freeman N, Tampakeras M, Levy J, Tchelet A, Eyal E, Berkovich E, Eliaz RE, Abler V, Grossman I, Fitzer-Attas C, Tiwari A, Hayden MR, Kennedy JL, Lang AE, Knight J; ADAGIO investigators.

Brain. 2016 Jul;139(Pt 7):2050-62. doi: 10.1093/brain/aww109. Epub 2016 May 13.

PMID:
27190009
24.

e23D: database and visualization of A-to-I RNA editing sites mapped to 3D protein structures.

Solomon O, Eyal E, Amariglio N, Unger R, Rechavi G.

Bioinformatics. 2016 Jul 15;32(14):2213-5. doi: 10.1093/bioinformatics/btw204. Epub 2016 Apr 19.

PMID:
27153640
25.

Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.

Hauser RA, Abler V, Eyal E, Eliaz RE.

Int J Neurosci. 2016 Oct;126(10):942-6. doi: 10.3109/00207454.2016.1154552. Epub 2016 Mar 18.

PMID:
26988747
26.

Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations.

Stephen J, Vilboux T, Haberman Y, Pri-Chen H, Pode-Shakked B, Mazaheri S, Marek-Yagel D, Barel O, Di Segni A, Eyal E, Hout-Siloni G, Lahad A, Shalem T, Rechavi G, Malicdan MC, Weiss B, Gahl WA, Anikster Y.

Eur J Hum Genet. 2016 Aug;24(9):1268-73. doi: 10.1038/ejhg.2016.5. Epub 2016 Feb 17.

27.

The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA.

Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, Peer E, Kol N, Ben-Haim MS, Dai Q, Di Segni A, Salmon-Divon M, Clark WC, Zheng G, Pan T, Solomon O, Eyal E, Hershkovitz V, Han D, Doré LC, Amariglio N, Rechavi G, He C.

Nature. 2016 Feb 25;530(7591):441-6. doi: 10.1038/nature16998. Epub 2016 Feb 10.

28.

Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.

Hale ME, Zimmerman TR, Eyal E, Malamut R.

J Opioid Manag. 2015 Nov-Dec;11(6):507-18. doi: 10.5055/jom.2015.0304.

PMID:
26728648
29.

TECPR2 mutations cause a new subtype of familial dysautonomia like hereditary sensory autonomic neuropathy with intellectual disability.

Heimer G, Oz-Levi D, Eyal E, Edvardson S, Nissenkorn A, Ruzzo EK, Szeinberg A, Maayan C, Mai-Zahav M, Efrati O, Pras E, Reznik-Wolf H, Lancet D, Goldstein DB, Anikster Y, Shalev SA, Elpeleg O, Ben Zeev B.

Eur J Paediatr Neurol. 2016 Jan;20(1):69-79. doi: 10.1016/j.ejpn.2015.10.003. Epub 2015 Oct 22.

PMID:
26542466
30.

High metallothionein predicts poor survival in glioblastoma multiforme.

Mehrian-Shai R, Yalon M, Simon AJ, Eyal E, Pismenyuk T, Moshe I, Constantini S, Toren A.

BMC Med Genomics. 2015 Oct 22;8:68. doi: 10.1186/s12920-015-0137-6.

31.

SLC1A4 mutations cause a novel disorder of intellectual disability, progressive microcephaly, spasticity and thin corpus callosum.

Heimer G, Marek-Yagel D, Eyal E, Barel O, Oz Levi D, Hoffmann C, Ruzzo EK, Ganelin-Cohen E, Lancet D, Pras E, Rechavi G, Nissenkorn A, Anikster Y, Goldstein DB, Ben Zeev B.

Clin Genet. 2015 Oct;88(4):327-35. doi: 10.1111/cge.12637. Epub 2015 Jul 28.

PMID:
26138499
32.

Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users.

Shram MJ, Cohen-Barak O, Chakraborty B, Bassan M, Schoedel KA, Hallak H, Eyal E, Weiss S, Gilgun-Serki Y, Sellers EM, Faulknor J, Spiegelstein O.

J Clin Psychopharmacol. 2015 Aug;35(4):396-405. doi: 10.1097/JCP.0000000000000347. Erratum in: J Clin Psychopharmacol. 2016 Oct;36(5):537. Gilgun, Yossi [corrected to Gilgun-Serki, Yossi].

PMID:
26082975
33.

Stem cells. m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation.

Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N, Salmon-Divon M, Hershkovitz V, Peer E, Mor N, Manor YS, Ben-Haim MS, Eyal E, Yunger S, Pinto Y, Jaitin DA, Viukov S, Rais Y, Krupalnik V, Chomsky E, Zerbib M, Maza I, Rechavi Y, Massarwa R, Hanna S, Amit I, Levanon EY, Amariglio N, Stern-Ginossar N, Novershtern N, Rechavi G, Hanna JH.

Science. 2015 Feb 27;347(6225):1002-6. doi: 10.1126/science.1261417. Epub 2015 Jan 1.

34.

The anisotropic network model web server at 2015 (ANM 2.0).

Eyal E, Lum G, Bahar I.

Bioinformatics. 2015 May 1;31(9):1487-9. doi: 10.1093/bioinformatics/btu847. Epub 2015 Jan 6.

35.

Tracking the mammary architectural features and detecting breast cancer with magnetic resonance diffusion tensor imaging.

Nissan N, Furman-Haran E, Feinberg-Shapiro M, Grobgeld D, Eyal E, Zehavi T, Degani H.

J Vis Exp. 2014 Dec 15;(94). doi: 10.3791/52048.

36.

Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial.

Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O; Rasagiline-for-MSA investigators.

Lancet Neurol. 2015 Feb;14(2):145-52. doi: 10.1016/S1474-4422(14)70288-1. Epub 2014 Dec 8.

PMID:
25498732
37.

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.

Smith KM, Eyal E, Weintraub D; ADAGIO Investigators.

JAMA Neurol. 2015 Jan;72(1):88-95. doi: 10.1001/jamaneurol.2014.2472.

PMID:
25420207
38.

Characterizing of functional human coding RNA editing from evolutionary, structural, and dynamic perspectives.

Solomon O, Bazak L, Levanon EY, Amariglio N, Unger R, Rechavi G, Eyal E.

Proteins. 2014 Nov;82(11):3117-31. doi: 10.1002/prot.24672. Epub 2014 Sep 3.

PMID:
25136968
39.

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.

Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S; ANDANTE study investigators.

Mov Disord. 2014 Jul;29(8):1028-34. doi: 10.1002/mds.25877. Epub 2014 Jun 11.

40.

Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial.

Jankovic J, Berkovich E, Eyal E, Tolosa E.

Parkinsonism Relat Disord. 2014 Jun;20(6):640-3. doi: 10.1016/j.parkreldis.2014.02.024. Epub 2014 Mar 5.

PMID:
24637126
41.

Standardization of radiological evaluation of dynamic contrast enhanced MRI: application in breast cancer diagnosis.

Furman-Haran E, Feinberg MS, Badikhi D, Eyal E, Zehavi T, Degani H.

Technol Cancer Res Treat. 2014 Oct;13(5):445-54. doi: 10.7785/tcrtexpress.2013.600263. Epub 2013 Aug 31.

42.

A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study.

Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, Zikich D, Levy D, Kubi A, Eyal E, Onn A, Cohen Y, Barshack I, Schachter J, Markel G.

Biomarkers. 2013 Sep;18(6):502-8. doi: 10.3109/1354750X.2013.816777. Epub 2013 Jul 29.

PMID:
23902289
43.

Advantages and drawbacks of breast DTI.

Furman-Haran E, Eyal E, Shapiro-Feinberg M, Nissan N, Grobgeld D, Weisenberg N, Degani H.

Eur J Radiol. 2012 Sep;81 Suppl 1:S45-7. doi: 10.1016/S0720-048X(12)70017-7. No abstract available.

PMID:
23083598
44.

A congenital neutrophil defect syndrome associated with mutations in VPS45.

Vilboux T, Lev A, Malicdan MC, Simon AJ, Järvinen P, Racek T, Puchalka J, Sood R, Carrington B, Bishop K, Mullikin J, Huizing M, Garty BZ, Eyal E, Wolach B, Gavrieli R, Toren A, Soudack M, Atawneh OM, Babushkin T, Schiby G, Cullinane A, Avivi C, Polak-Charcon S, Barshack I, Amariglio N, Rechavi G, van der Werff ten Bosch J, Anikster Y, Klein C, Gahl WA, Somech R.

N Engl J Med. 2013 Jul 4;369(1):54-65. doi: 10.1056/NEJMoa1301296. Epub 2013 Jun 5.

45.

MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth.

Nemlich Y, Greenberg E, Ortenberg R, Besser MJ, Barshack I, Jacob-Hirsch J, Jacoby E, Eyal E, Rivkin L, Prieto VG, Chakravarti N, Duncan LM, Kallenberg DM, Galun E, Bennett DC, Amariglio N, Bar-Eli M, Schachter J, Rechavi G, Markel G.

J Clin Invest. 2013 Jun;123(6):2703-18.

46.

Global regulation of alternative splicing by adenosine deaminase acting on RNA (ADAR).

Solomon O, Oren S, Safran M, Deshet-Unger N, Akiva P, Jacob-Hirsch J, Cesarkas K, Kabesa R, Amariglio N, Unger R, Rechavi G, Eyal E.

RNA. 2013 May;19(5):591-604. doi: 10.1261/rna.038042.112. Epub 2013 Mar 8.

47.

Detection of BCR-ABL1 mutations in chronic myeloid leukaemia by massive parallel sequencing.

Eyal E, Tohami T, Amir A, Cesarkas K, Jacob-Hirsch J, Volchek Y, Nagler A, Rechavi G, Amariglio N.

Br J Haematol. 2013 Feb;160(4):477-86. doi: 10.1111/bjh.12171. Epub 2012 Dec 17.

PMID:
23252482
48.

Parametric diffusion tensor imaging of the breast.

Eyal E, Shapiro-Feinberg M, Furman-Haran E, Grobgeld D, Golan T, Itzchak Y, Catane R, Papa M, Degani H.

Invest Radiol. 2012 May;47(5):284-91. doi: 10.1097/RLI.0b013e3182438e5d.

PMID:
22472798
49.

Mutagen-specific mutation signature determines global microRNA binding.

Greenberg E, Rechavi G, Amariglio N, Solomon O, Schachter J, Markel G, Eyal E.

PLoS One. 2011;6(11):e27400. doi: 10.1371/journal.pone.0027400. Epub 2011 Nov 9.

50.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.

Lancet Neurol. 2011 May;10(5):415-23. doi: 10.1016/S1474-4422(11)70073-4. Epub 2011 Apr 7. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.

PMID:
21482191

Supplemental Content

Support Center